An Ad5-vectored HIV-1 vaccine elicits cell-mediated immunity but does not affect disease progression in HIV-1-infected male subjects: Results from a randomized placebo-controlled trial (The step study)

Journal of Infectious Diseases

Volumn 203, Issue 6, 2011, Pages 765-772

  Fitzgerald, Daniel W ^a   Janes, H ^b   Robertson, M ^c   Coombs, R ^d   Frank, I ^e   Gilbert, P ^b   Loufty, M ^f   Mehrotra, D ^c   Duerr, A ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; HLA ANTIGEN CLASS 1; HLA B27 ANTIGEN; HLA B57 ANTIGEN; HLA B58 ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; PLACEBO; UNCLASSIFIED DRUG; VIRUS RNA;

ADENOVIRUS 5; ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CELLULAR IMMUNITY; CONTROLLED STUDY; DISEASE CONTROL; DISEASE COURSE; DISEASE FREE SURVIVAL; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VIRUS LOAD;

ADENOVIRUSES, HUMAN; ADULT; AIDS VACCINES; ANTI-RETROVIRAL AGENTS; BLOTTING, WESTERN; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; CIRCUMCISION, MALE; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; GENETIC VECTORS; HIV INFECTIONS; HIV-1; HUMANS; IMMUNITY, CELLULAR; MALE; MIDDLE AGED; PLACEBOS; PROPORTIONAL HAZARDS MODELS; RNA, VIRAL; VIRAL LOAD; YOUNG ADULT;

EID: 79952324470     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jiq114     Document Type: Article

References (46)

1. Altfeld M, Kalife ET, Qi Y, et al. HLA alleles associated with delayed progression to AIDS contribute strongly to the initial CD8(+) T cell response against HIV-1. PLoS Med 2006; 3:e403.
2. Borrow P, Lewicki H, Hahn BH, Shaw GM, Oldstone MB. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 1994; 68:6103-6110. (Pubitemid 24258634)
3. Emu B, Sinclair E, Hatano H, et al. HLA class I-restricted T cell responses may contribute to the control of human immunodeficiency virus infection, but such responses are not always necessary for long-term virus control. J Virol 2008; 82:5398-5407. (Pubitemid 351705247)
4. Klein MR, van Baalen CA, Holwerda AM, et al. Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics. J Exp Med 1995; 181:1365-1372.
5. Koup RA, Safrit JT, Cao Y, et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994; 68:4650-4655. (Pubitemid 24183063)
6. Pereyra F, Addo MM, Kaufmann DE, et al. Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. J Infect Dis 2008; 197:563-571. (Pubitemid 351321534)
7. Rosenberg ES, Billingsley JM, Caliendo AM, et al. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science 1997; 278:1447-1450. (Pubitemid 27509814)
8. Streeck H, Jolin JS, Qi Y, et al. Human immunodeficiency virus type 1-specific CD8+ T cell responses during primary infection are major determinants of the viral set point and loss of CD4+ T cells. J Virol 2009; 83:7641-7648.
9. Amara RR, Villinger F, Altman JD, et al. Control of a mucosal challenge and revention of AIDS by a multiprotein DNA/MVA vaccine. Science 2001; 292:69-74. (Pubitemid 32289126)
10. Barouch DH, Santra S, Schmitz JE, et al. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 2000; 290:486-492.
11. Shiver JW, Fu TM, Chen L, et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 2002; 415:331-335. (Pubitemid 34087555)
12. Buchbinder SP, Mehrotra DV, Duerr A, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008; 372:1881-1893.
13. Gurunathan S, Habib RE, Baglyos L, et al. Use of predictive markers of HIV disease progression in vaccine trials. Vaccine 2009; 27:1997-2015.
14. Margolick JB, Farzadegan H, Hoover DR, Saah AJ. Relationship between infectious cell-associated human immunodeficiency virus type 1 load, T lymphocyte subsets, and stage of infection in homosexual men. J Infect Dis 1996; 173:468-471. (Pubitemid 26042452)
15. Mellors JW, Munoz A, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997; 126:946-954. (Pubitemid 27255797)
16. Priddy FH, Brown D, Kublin J, et al. Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults. Clin Infect Dis 2008; 46:1769-1781. (Pubitemid 351706778)
17. Centers for Disease Control and Prevention. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. JAMA 1993; 269:729-730.
18. Fitzgerald DW, Marotte C, Verdier RI, Johnson WD Jr., Pape JW. Comprehension during informed consent in a less-developed country. Lancet 2002; 360:1301-1302. (Pubitemid 35284623)
19. Panel on Antiretroviral Guidelines for Adults, Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services, 2008; 1-139. http://www.aidsinfo.nih. gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed 1 June 2009.
20. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a Public Health approach, 2006 Revision. Geneva, Switzerland: World Health Organization, 2006.
21. Hammer SM, Eron JJ Jr., Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008; 300:555-570.
22. Jarrin I, Geskus R, Bhaskaran K, et al. Gender differences in HIV progression to AIDS and death in industrialized countries: slower disease progression following HIV seroconversion in women. Am J Epidemiol 2008; 168:532-540.
23. Holm S. A simple sequentially rejective multiple test procedure. Scandinavian Journal of Statistics 1979; 6:65-70.
24. Halloran ME, Struchiner CJ. Causal inference in infectious diseases. Epidemiology 1995; 6:142-151.
25. Rosenbaum PR. The consequences of adjustment for a concomitant variable that has been affected by the treatment. Journal of the Royal Statistical Society, Ser A 1984; 147:656-666.
26. Shepherd BE, Gilbert PB, Jemiai Y, Rotnitzky A. Sensitivity analyses comparing outcomes only existing in a subset selected post-randomization, conditional on covariates, with application to HIV vaccine trials. Biometrics 2006; 62:332-342. (Pubitemid 43926638)
27. Fellay J, Shianna KV, Ge D, et al. A whole-genome association study of major determinants for host control of HIV-1. Science 2007; 317:944-947. (Pubitemid 47301321)
28. Kaslow RA, Carrington M, Apple R, et al. Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nat Med 1996; 2:405-411. (Pubitemid 26193012)
29. Migueles SA, Sabbaghian MS, Shupert WL, et al. HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. Proc Natl Acad Sci U S A 2000; 97:2709-2714. (Pubitemid 30159236)
30. Miura T, Brockman MA, Schneidewind A, et al. HLA-B57/B*5801 human immunodeficiency virus type 1 elite controllers select for rare gag variants associated with reduced viral replication capacity and strong cytotoxic T-lymphocyte [corrected] recognition. J Virol 2009; 83:2743-2755.
31. Schneidewind A, Brockman MA, Yang R, et al. Escape from the dominant HLA-B27-restricted cytotoxic T-lymphocyte response in Gag is associated with a dramatic reduction in human immunodeficiency virus type 1 replication. J Virol 2007; 81: 12382-12393. (Pubitemid 350085852)
32. Rubin DB. Multiple imputation for nonresponse in surveys. Hoboken, New Jersey: John Wiley and Sons, 1987.
33. Van Buuren S, Brand JP, Groothuis-Oudshoorn CGM, Rubin DB. Fully conditional specification in multivariate imputation. J Stat Comput Simulation 2006; 76:1049-1064. (Pubitemid 44843816)
34. Hughes JP. Mixed effects models with censored data with application to HIV RNA levels. Biometrics 1999; 55:625-629. (Pubitemid 29302594)
35. Liang KY, Zeger SL. Longitudinal data analysis using the generalized linear models. Biometrika 1986; 73:13-22.
36. Robins JM, Rotnitzky A, Zhao LP. Analysis of semiparametric regression models for repeated outcomes in the presence of missing data. Am Stat Assoc 1995; 90:106-121.
37. McElrath MJ, De Rosa SC, Moodie Z, et al. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 2008; 372:1894-1905.
38. Betts MR, Nason MC, West SM, et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 2006; 107:4781-4789. (Pubitemid 43882629)
39. Almeida JR, Price DA, Papagno L, et al. Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover. J Exp Med 2007; 204:2473-2485. (Pubitemid 47529331)
40. Streeck H, Brumme ZL, Anastario M, et al. Antigen load and viral sequence diversification determine the functional profile of HIV-1-specific CD8+ T cells. PLoS Med 2008; 5:e100.
41. Harari A, Cellerai C, Enders FB, et al. Skewed association of polyfunctional antigen-specific CD8 T cell populations with HLA-B genotype. Proc Natl Acad Sci U S A 2007; 104:16233-16238. (Pubitemid 350099390)
42. Brumme ZL, Brumme CJ, Carlson J, et al. Marked epitope- and allele-specific differences in rates of mutation in human immunodeficiency type 1 (HIV-1) Gag, Pol, and Nef cytotoxic T-lymphocyte epitopes in acute/early HIV-1 infection. J Virol 2008; 82:9216-9217.
43. Cao J, McNevin J, Malhotra U, McElrath MJ. Evolution of CD8+ T cell immunity and viral escape following acute HIV-1 infection. J Immunol 2003; 171:3837-3846. (Pubitemid 37254590)
44. Li B, Gladden AD, Altfeld M, et al. Rapid reversion of sequence polymorphisms dominates early human immunodeficiency virus type 1 evolution. J Virol 2007; 81:193-201. (Pubitemid 44975160)
45. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009; 361:2209-2210.
46. Kaslow RA, Rivers C, Tang J, et al. Polymorphisms in HLA class I genes associated with both favorable prognosis of human immunodeficiency virus (HIV) type 1 infection and positive cytotoxic T-lymphocyte responses to ALVAC-HIV recombinant canarypox vaccines. J Virol 2001; 75:8681-8689. (Pubitemid 32768972)